Phaseline

Targets › SOD1

SOD1 (Superoxide dismutase [Cu-Zn]): drug programs, companies and trials

7 programs from 7 companies in 10 trials: 6 Phase 1, 2 Phase 2, 1 Phase 4, 1 Phase 3; Neurology, Other, Oncology; next expected readout Jan 2027.

Destroys radicals which are normally produced within the cells and which are toxic to biological systems. Catalyzes the oxidation of hydrogen sulfide (H2S) to sulfate, playing an important role in detoxifying H2S and limiting the accumulation of reactive sulfur species (RSS) such as persulfides and polysulfides. (UniProt, P00441)

Open in Phaseline: the race on SOD1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BiogenTofersen
SOD1 mRNA antisense inhibitor
SOD1Phase 4Amyotrophic Lateral Sclerosis; Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation; ALS (Amyotrophic Lateral Sclerosis)May 2027
West China Hospitalsuperoxide dismutase skin spray
antioxidant enzyme that catalyzes the dismutation of superoxide radicals
SOD1, SOD2, SOD3Phase 2Radiation-induced DermatitisJan 2027
Insmed Gene TherapyINS1202
Gene therapy targeting SOD1 mutations
SOD1Phase 1Amyotrophic Lateral SclerosisMar 2030
UniQure BiopharmaAMT-162
Self-complementary AAV serotype rh10 vector delivering miRNA targeting SOD1
SOD1Phase 1Amyotrophic Lateral SclerosisJun 2031
Regeneron PharmaceuticalsALN-SOD
SOD1 mRNA inhibitor (RNAi therapeutic)
SOD1Phase 1Amyotrophic Lateral Sclerosis (ALS)Mar 2032
Ractigen Therapeutics.RAG-17
SOD1 mRNA targeting siRNA
SOD1Phase 1Amyotrophic Lateral Sclerosis–
Beijing Tiantan HospitalY-4 tablet
Fixed-dose combination of pregabalin (GABA analog/anticonvulsant) and riluzole (glutamate
GABRA1, SOD1Phase 1Healthy Male and Female Subjects–

Conditions

Amyotrophic Lateral Sclerosis (4) Healthy Male and Female Subjects (2) Radiation-induced Dermatitis (1) Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation (1) ALS (Amyotrophic Lateral Sclerosis) (1) Amyotrophic Lateral Sclerosis (ALS) (1)

Modalities

small molecule (4), other (2), protein or peptide (1)

Companies

Beijing Tiantan Hospital (1) West China Hospital (1) UniQure Biopharma (1) Biogen (1) Regeneron Pharmaceuticals (1) Insmed Gene Therapy (1) Ractigen Therapeutics. (1)

Related targets

GABRA1 (1) SOD2 (1) SOD3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.